# US 2021/0330650 A1 · Spirochromane derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330650 A1
- Document ID: US20210330650A1
- Status: Published application
- Kind: A1
- Application number: 17/259,972
- Filed: 2019-07-12
- Published: 2021-10-28
- Earliest claimed: 2018-07-13
- Assignees: Richter Gedeon Nyrt.
- Applicants: Richter Gedeon Nyrt.
- Inventors: János ÉLES; Katalin DUDÁSNÉ MOLNÁR; István LEDNECZKI; Pál TOPOLCSÁNYI; Anita HORVÁTH; Zsolt NÉMETHY; György István LÉVAY
- Web page: https://patentgrep.com/patent/US20210330650A1

## CPC

- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D 471/04: Ortho-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 491/20: Spiro-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to spirochromane derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing them and to their use as modulators of α7 nicotinic acetylcholine receptor activity in a mammalian subject.

## Claims

### Claim 1

A compound of formula (I),
wherein:
A is a five or six membered heterocycle;
B is a six membered carbocycle or heterocycle;
X is C or N;
Y is C or N;
Z is C or N;
W is O or S;
R1 is H, C1-6alkyl, halogen or haloC1-6alkyl;
R2 is H or O;
R3 is H, C1-6alkyl, halogen, haloC1-6alkyl or C1-6alkoxy;
R4 is H or C1-6alkyl;
R5 is H or C1-6alkyl;
n and m are independently 1 or 2;
is a single- or double-bond;
or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein
A is five membered heterocycle, wherein the members of the ring are selected from the group consisting of carbon, nitrogen, oxygen, and sulphur;
B is a six membered carbocycle or a heterocycle, wherein the members of the ring are selected from the group consisting of carbon, nitrogen, oxygen, and sulphur;
X is C;
Y is C;
Z is C or N;
W is O or S;
R1 is H, C1-6alkyl, halogen or halo C1-6alkyl;
R2 is H or O;
R3 is H, C1-6alkyl, halogen, haloC1-6alkyl or C1-6alkoxy;
R4 is H;
R5 is H;
n and m are independently 1 or 2;
is a single- or double-bond.

### Claim 3

A compound of formula (II),
wherein
V is C or S;
Z is C or N
W is O or S;
R1a is H, C1-6alkyl, or haloC1-6alkyl;
R1b is H, C1-6alkyl, halogen, or haloC1-6alkyl;
R1c is H, C1-6alkyl, halogen, or haloC1-6alkyl when V is carbon; or R1c is absent when
V is sulphur;
R2 is H or O;
R3 is H, C1-6alkyl, halogen, haloC1-6alkyl, or C1-6alkoxy;
n and m are independently 1 or 2;
is a single- or double-bond;
or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof.

### Claim 4 (depends on 3)

A compound according to claim 3, wherein
V is C;
Z is C or N;
W is O;
R1a is H, C1-6alkyl, or haloC1-6alkyl;
R1b is H, C1-6alkyl, halogen, or haloC1-6alkyl;
R1c is H, C1-6alkyl, halogen, or haloC1-6alkyl;
R2 is H or O;
R3 is H, C1-6alkyl, halogen, or haloC1-6alkyl;
n and m are independently 1 or 2;
is a single- or double-bond.

### Claim 5 (depends on 1, 4)

A compound according to any one of claim 1 or 4, selected from the group of:
6′-Fluoro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6-chloro-N-[(1-methyl-1H-indol-5-yl)methyl]-4-oxo-3,4-dihydrospiro[1-benzopyran-2,4′-piperidine]-1′-carboxamide;
6′-chloro-N-[(1-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
7′-fluoro-N-[(1-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
N-[(1-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6-chloro-N-[(1-methyl-1H-indol-5-yl)methyl]-3,4-dihydrospiro[1]-benzopyran-2,4′-piperidine]-1′-carboxamide;
N-[(3-chloro-1-methyl-1H-indol-5-yl)methyl]-6′-fluoro-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′-chloro-N-[(1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′-fluoro-N-[(1-methyl-1H-indol-5-yl)methyl]-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′-fluoro-N-[(1-methyl-1H-indol-5-yl)methyl]spiro[azetidine-3,2′-chromene]-1-carboxamide;
N-[(1-methyl-1H-indol-5-yl)methyl]-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′-chloro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′,8′-difluoro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
7′-chloro-N-[(2-chloro-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
7′-chloro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
7′-fluoro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-6′-(trifluoromethyl)-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
N-[(1-methyl-1H-indol-5-yl)methyl]-4′-oxo-7′-(trifluoromethyl)-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-7′-(trifluoromethyl)-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
6′,8′-dichloro-N-[(2-methyl-1H-indol-5-yl)methyl]-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
7′-fluoro-4′-oxo-N-{[2-(trifluoromethyl)-1H-indol-5-yl]methyl}-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
N-{[2-(difluoromethyl)-1H-indol-5-yl]methyl}-7′-fluoro-4′-oxo-3′,4′-dihydrospiro[azetidine-3,2′-[1]benzopyran]-1-carboxamide;
or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A compound according to any one of claims 1 to 5, for use in the treatment or prevention of a disease associated with α7 nicotinic acetylcholine receptor activity.

### Claim 7 (depends on 6)

A compound according to claim 6, wherein the disease is selected from the group of psychotic disorders, including, but not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder or psychotic disorder not otherwise specified, cognitive impairment, including, but not limited to, cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, HIV associated dementia, frontotemporal dementia, Lewy body dementia, vascular dementia, cerebrovascular disease or other dementia states and dementia associated to other degenerative disorders, including, but not limited to, amyotrophic lateral sclerosis, other acute or sub-acute conditions that may cause cognitive decline, including, but not limited to, delirium, traumatic brain injury, senile dementia, mild cognitive impairment, Down's syndrome, depression and cognitive deficit related to other diseases, and dyskinetic disorders including, but not limited to, Parkinson's disease, neuroleptic-induced parkinsonism, or tardive dyskinesias, depression and mood disorders, including, but not limited to, depressive disorders and episodes, bipolar disorders, cyclothymic disorder, and bipolar disorder not otherwise specified, other mood disorders, substance-induced mood disorder and mood disorder not otherwise specified, anxiety disorders, panic disorder and panic attacks, obsessive compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to a general medical condition, substance-induced anxiety disorder, phobias, and anxiety disorder not otherwise specified, substance related disorders, including, but not limited to, substance use or substance-induced disorders, including, but not limited to, alcohol-, nicotine-, amphetamine-, phencyclidine-, opioid-, cannabis-, cocaine-, caffeine-, hallucinogen-, inhalant-, sedative-, hypnotic-, anxiolytic-, polysubstance- or other substance-related disorders, sleep disorders, including, but not limited to, narcolepsy, dyssomnias, primary hypersomnia, breathing-related sleep disorders, circadian rhythm sleep disorder and dyssomnia not otherwise specified, parasomnias, sleep terror disorder, sleepwalking disorder and parasomnia not otherwise specified, sleep disorders related to another mental disorder, sleep disorder due to a general medical condition and substance-induced sleep disorder, metabolic and eating disorders, including, but not limited to, anorexia nervosa, bulimia nervosa, obesity, compulsive eating disorder, binge eating disorder and eating disorder not otherwise specified, diabetes mellitus, ulcerative colitis, Crohn's disease, irritable bowel syndrome, autism spectrum disorders, including, but not limited to, autistic disorder, Asperger's disorder, Rett's disorder, childhood disintegrative disorder and pervasive developmental disorder not otherwise specified, attention deficit hyperactivity disorder, disruptive behaviour disorders, oppositional defiant disorder and disruptive behaviour disorder not otherwise specified, and tic disorders, including, but not limited to, Tourette's disorder, personality disorders, sexual dysfunctions such as sexual desire disorders, sexual arousal disorders, orgasmic disorders, sexual pain disorder, sexual dysfunction not otherwise specified, paraphilias, gender identity disorders, infertility, premenstrual syndrome and sexual disorders not otherwise specified, disorders of the respiratory system like cough, asthma, chronic obstructive pulmonary disease, lung inflammation, disorders of the cardiovascular system such as cardiac failure, heart arrhythmia, hypertension, inflammation, inflammatory and neuropathic pain, rheumatoid arthritis, osteoarthritis, allergy, sarcoidosis, psoriasis, ataxia, dystonia, systemic lupus erythematosus, mania, restless legs syndrome, progressive supranuclear palsy, epilepsy, myoclonus, migraine, amnesia, chronic fatigue syndrome, cataplexy, brain ischemia, multiple sclerosis, encephalomyelitis, jetlag, cerebral amyloid angiopathy, and sepsis.

### Claim 8 (depends on 7)

A compound according to claim 7, wherein the disease is selected from the group of cognitive impairment, schizophrenia, and autism.

### Claim 9 (depends on 1, 2, 3, 4, 5)

Use of compound according to any one of claims 1 to 5, for the manufacture of a medicament for the treatment or prevention of a disease associated with α7 nicotinic acetylcholine receptor activity.

### Claim 10 (depends on 9)

Use according to claim 9, wherein the disease is selected from the group of psychotic disorders, including, but not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder or psychotic disorder not otherwise specified, cognitive impairment, including, but not limited to, cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, HIV associated dementia, frontotemporal dementia, Lewy body dementia, vascular dementia, cerebrovascular disease or other dementia states and dementia associated to other degenerative disorders, including, but not limited to, amyotrophic lateral sclerosis, other acute or sub-acute conditions that may cause cognitive decline, including, but not limited to, delirium, traumatic brain injury, senile dementia, mild cognitive impairment, Down's syndrome, depression and cognitive deficit related to other diseases, and dyskinetic disorders including, but not limited to, Parkinson's disease, neuroleptic-induced parkinsonism, or tardive dyskinesias, depression and mood disorders, including, but not limited to, depressive disorders and episodes, bipolar disorders, cyclothymic disorder, and bipolar disorder not otherwise specified, other mood disorders, substance-induced mood disorder and mood disorder not otherwise specified, anxiety disorders, panic disorder and panic attacks, obsessive compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to a general medical condition, substance-induced anxiety disorder, phobias, and anxiety disorder not otherwise specified, substance related disorders, including, but not limited to, substance use or substance-induced disorders, including, but not limited to, alcohol-, nicotine-, amphetamine-, phencyclidine-, opioid-, cannabis-, cocaine-, caffeine-, hallucinogen-, inhalant-, sedative-, hypnotic-, anxiolytic-, polysubstance- or other substance-related disorders, sleep disorders, including, but not limited to, narcolepsy, dyssomnias, primary hypersomnia, breathing-related sleep disorders, circadian rhythm sleep disorder and dyssomnia not otherwise specified, parasomnias, sleep terror disorder, sleepwalking disorder and parasomnia not otherwise specified, sleep disorders related to another mental disorder, sleep disorder due to a general medical condition and substance-induced sleep disorder, metabolic and eating disorders, including, but not limited to, anorexia nervosa, bulimia nervosa, obesity, compulsive eating disorder, binge eating disorder and eating disorder not otherwise specified, diabetes mellitus, ulcerative colitis, Crohn's disease, irritable bowel syndrome, autism spectrum disorders, including, but not limited to, autistic disorder, Asperger's disorder, Rett's disorder, childhood disintegrative disorder and pervasive developmental disorder not otherwise specified, attention deficit hyperactivity disorder, disruptive behaviour disorders, oppositional defiant disorder and disruptive behaviour disorder not otherwise specified, and tic disorders, including, but not limited to, Tourette's disorder, personality disorders, sexual dysfunctions such as sexual desire disorders, sexual arousal disorders, orgasmic disorders, sexual pain disorder, sexual dysfunction not otherwise specified, paraphilias, gender identity disorders, infertility, premenstrual syndrome and sexual disorders not otherwise specified, disorders of the respiratory system like cough, asthma, chronic obstructive pulmonary disease, lung inflammation, disorders of the cardiovascular system such as cardiac failure, heart arrhythmia, hypertension, inflammation, inflammatory and neuropathic pain, rheumatoid arthritis, osteoarthritis, allergy, sarcoidosis, psoriasis, ataxia, dystonia, systemic lupus erythematosus, mania, restless legs syndrome, progressive supranuclear palsy, epilepsy, myoclonus, migraine, amnesia, chronic fatigue syndrome, cataplexy, brain ischemia, multiple sclerosis, encephalomyelitis, jetlag, cerebral amyloid angiopathy, and sepsis.

### Claim 11 (depends on 10)

Use according to claim 10, wherein the disease is cognitive impairment, schizophrenia, or autism.

### Claim 12 (depends on 1, 2, 3, 4, 5)

A method for the treatment or prevention of a disease associated with α7 nicotinic acetylcholine receptor activity comprising administering to a mammal in need of such treatment or prevention an effective amount of at least one compound according to any one of claims 1 to 5.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the disease is selected from the group of psychotic disorders, including, but not limited to, schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder or psychotic disorder not otherwise specified, cognitive impairment, including, but not limited to, cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, HIV associated dementia, frontotemporal dementia, Lewy body dementia, vascular dementia, cerebrovascular disease or other dementia states and dementia associated to other degenerative disorders, including, but not limited to, amyotrophic lateral sclerosis, other acute or sub-acute conditions that may cause cognitive decline, including, but not limited to, delirium, traumatic brain injury, senile dementia, mild cognitive impairment, Down's syndrome, depression and cognitive deficit related to other diseases, and dyskinetic disorders including, but not limited to, Parkinson's disease, neuroleptic-induced parkinsonism, or tardive dyskinesias, depression and mood disorders, including, but not limited to, depressive disorders and episodes, bipolar disorders, cyclothymic disorder, and bipolar disorder not otherwise specified, other mood disorders, substance-induced mood disorder and mood disorder not otherwise specified, anxiety disorders, panic disorder and panic attacks, obsessive compulsive disorder, posttraumatic stress disorder, acute stress disorder, generalized anxiety disorder, anxiety disorder due to a general medical condition, substance-induced anxiety disorder, phobias, and anxiety disorder not otherwise specified, substance related disorders, including, but not limited to, substance use or substance-induced disorders, including, but not limited to, alcohol-, nicotine-, amphetamine-, phencyclidine-, opioid-, cannabis-, cocaine-, caffeine-, hallucinogen-, inhalant-, sedative-, hypnotic-, anxiolytic-, polysubstance- or other substance-related disorders, sleep disorders, including, but not limited to, narcolepsy, dyssomnias, primary hypersomnia, breathing-related sleep disorders, circadian rhythm sleep disorder and dyssomnia not otherwise specified, parasomnias, sleep terror disorder, sleepwalking disorder and parasomnia not otherwise specified, sleep disorders related to another mental disorder, sleep disorder due to a general medical condition and substance-induced sleep disorder, metabolic and eating disorders, including, but not limited to, anorexia nervosa, bulimia nervosa, obesity, compulsive eating disorder, binge eating disorder and eating disorder not otherwise specified, diabetes mellitus, ulcerative colitis, Crohn's disease, irritable bowel syndrome, autism spectrum disorders, including, but not limited to, autistic disorder, Asperger's disorder, Rett's disorder, childhood disintegrative disorder and pervasive developmental disorder not otherwise specified, attention deficit hyperactivity disorder, disruptive behaviour disorders, oppositional defiant disorder and disruptive behaviour disorder not otherwise specified, and tic disorders, including, but not limited to, Tourette's disorder, personality disorders, sexual dysfunctions such as sexual desire disorders, sexual arousal disorders, orgasmic disorders, sexual pain disorder, sexual dysfunction not otherwise specified, paraphilias, gender identity disorders, infertility, premenstrual syndrome and sexual disorders not otherwise specified, disorders of the respiratory system like cough, asthma, chronic obstructive pulmonary disease, lung inflammation, disorders of the cardiovascular system such as cardiac failure, heart arrhythmia, hypertension, inflammation, inflammatory and neuropathic pain, rheumatoid arthritis, osteoarthritis, allergy, sarcoidosis, psoriasis, ataxia, dystonia, systemic lupus erythematosus, mania, restless legs syndrome, progressive supranuclear palsy, epilepsy, myoclonus, migraine, amnesia, chronic fatigue syndrome, cataplexy, brain ischemia, multiple sclerosis, encephalomyelitis, jetlag, cerebral amyloid angiopathy, and sepsis.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the disease is selected from the group of cognitive impairment, schizophrenia, and autism.

### Claim 15 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition comprising as active ingredient a compound according to any one of claims 1 to 5 and at least one pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

A pharmaceutical composition according to claim 15, wherein the composition further comprises at least one other active ingredient.

### Claim 17 (depends on 16)

A pharmaceutical composition according to claim 16, wherein the other active ingredient(s) are selected from the group of acetylcholinesterase inhibitors, NMDA receptor antagonists, beta-secretase inhibitors, antipsychotics, GABAA receptor alpha5 subunit NAMs or PAMs, histamine H3 receptor antagonists, 5-HT6 receptor antagonists, M1 or M4 mAChR agonists or PAMs, mGluR2 antagonists or NAMs or PAMs, and levodopa.

### Claim 18 (depends on 1, 2, 3, 4, 5)

Combination of a compound according to any one of claims 1 to 5 and at least one other active ingredient for use in the treatment or prevention of a disease associated with α7 nicotinic acetylcholine receptor activity.

### Claim 19 (depends on 18)

Combination according to claim 18, wherein the other active ingredient(s) are selected from the group of acetylcholinesterase inhibitors, NMDA receptor antagonists, beta-secretase inhibitors, antipsychotics, GABAA receptor alpha5 subunit NAMs or PAMs, histamine H3 receptor antagonists, 5-HT6 receptor antagonists, M1 or M4 mAChR agonists or PAMs, mGluR2 antagonists or NAMs or PAMs, and levodopa.

### Claim 20 (depends on 3)

Process for the manufacture of compounds of formula (II) according to claim 3, characterized by reacting a compound of formula (III)
wherein the meaning of R3 is described above for compound of formula (II)—with a compound of formula (IV)
wherein the meaning of n and m is described above for compound of formula (II)—either in two separated steps via formula (VII)
wherein the meaning of n and m is described above for compound of formula (II), or directly in one step to provide a compound of formula (V)
wherein the meaning of R3, n and m is as described above for formula (II)—which is then reacted with
a.) hydrogen chloride to provide formula (VI)
wherein the meaning of R3, n and m is as described above for formula (II),
b.) complex hydrides to provide formula (VIII)
wherein the meaning of R3, n and m is as described above for formula (II)—then compound of formula (VIII) is reduced with triethylphosphine to provide formula (IX)
wherein the meaning of R3, n and m is as described above for formula (II)—then the obtained derivative of formula (IX) or formula (VI)—is reacted with formula (X)
wherein the meaning of R1a, R1b, R1c, V, and Z is as described above for formula (II)
providing formula (II)
wherein the meaning of R1a, R1b, R1c, R2, R3, V, Z, n, m, and W are as described above for formula (II).

### Claim 21

A compound of (1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-5-yl)methanamine.

### Claim 22

A compound of {3-chloro-1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl}methanamine.

### Claim 23

A compound of {3-Bromo-1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl}methanamine.

### Claim 24

A compound of 3′,4′-Dihydrospiro[azetidine-3,2′-pyrano[3,2-b]pyridin]-4′-one hydrochloride.
